AstraZeneca Pharma India Limited has strengthened its senior management team with the appointment of two experienced pharmaceutical professionals to key directorial positions. The Board of Directors approved these strategic appointments based on recommendations from the Nomination and Remuneration Committee, as disclosed under Regulation 30 of SEBI regulations.

Key Appointments

The company has made two significant appointments effective January 12, 2026:

Both positions are full-time employment roles that will contribute to the company's strategic business operations across critical therapeutic areas and market channels.

Ms. Aditi Dayarus Mehta - Oncology Leadership

Ms. Mehta brings over 15 years of pharmaceutical industry experience with expertise in Commercial Leadership, Strategy, and Change Management. Her professional journey includes:

• Previous Role: Business Unit Director at Pfizer India, leading the Innovative Vaccine portfolio
• Pfizer Experience: Over a decade across multiple roles including Oncology, Access, and Commercial Excellence
• Early Career: Business Analyst at Bristol Myers Squibb
• Education: Bachelor of Pharmacy (Gold Medallist) from K.M. Kundnani College of Pharmacy, Mumbai

Her track record demonstrates transformative commercial growth leadership rooted in equity and excellence values, with strategic orientation for leading collaborative teams.

Mr. Nitin Bindal - Institutional Business Expertise

Mr. Bindal contributes 17 years of diverse pharmaceutical industry experience across multiple therapeutic areas and functions:

Career Highlights:

• Bristol Myers Squibb: Business Unit Director – Oncology & Haematology, leading access and market penetration for immunotherapies across 20 indications
• Johnson & Johnson: Eight years in key roles including National Sales Head, Senior Marketing Manager in Oncology, and Neuroscience Business Unit leadership
• Additional Experience: Strategic and commercial roles at Novartis, Wockhardt, and Smart Analyst

Educational Background:

• Chemical Engineering degree from IIT Bombay
• Post Graduate Program in Management for Executives from UCLA Anderson School of Management, Los Angeles

Strategic Implications

These appointments underscore AstraZeneca Pharma India's commitment to strengthening its leadership in critical business areas. The oncology focus aligns with the growing importance of cancer therapeutics in the Indian pharmaceutical market, while the institutional business and public channels directorship addresses the company's distribution and access strategies.

Both appointees bring extensive experience from leading pharmaceutical companies including Pfizer, Bristol Myers Squibb, and Johnson & Johnson, providing valuable industry insights and established networks that will benefit AstraZeneca's operations in India.

AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, to import and distribute a new cancer treatment drug in the Indian market.

Regulatory Approval Confirmed

The company has obtained official permission to import for sale and distribution of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100mg (r-DNA origin), which will be marketed under the brand name Datverzo. This approval represents a significant milestone as it introduces a new therapeutic option to the Indian pharmaceutical market.

Treatment Indication and Patient Criteria

Datopotamab Deruxtecan is specifically indicated for treating adult patients with a particular type of breast cancer. The drug targets patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

The treatment is designated for patients who meet specific clinical criteria including breast cancer classification of IHC 0, IHC 1+ or IHC 2+/ISH-, prior treatment history with endocrine-based therapy and chemotherapy, and unresectable or metastatic disease stage.

Market Authorization and Implementation

The CDSCO approval paves the way for AstraZeneca Pharma India to market Datopotamab Deruxtecan in India for the specified indication. The company has confirmed that marketing activities remain subject to receiving any additional statutory approvals that may be required for full commercial launch.

This regulatory milestone represents AstraZeneca Pharma India's continued commitment to bringing innovative cancer treatments to Indian patients, particularly those with specific breast cancer subtypes who have limited treatment options after standard therapies.